Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGT1 | P19440 | 1/20 | 0.42 |
| ▸ | GPR142 | Q7Z601 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CPB1 | P15086 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1667207 | 1.00 | GGT1 (0.42) | GGT1GPR142SIGMAR1MMECPB2 | |
| Imidazole SCHEMBL27889109 | 0.90 | GPR142 (0.39) | GGT1GPR142SIGMAR1MMECPB2 | |
| SCHEMBL27776883 | 0.90 | GPR142 (0.39) | GPR142SIGMAR1KMT2AHPGDNPC1 | |
| SCHEMBL466341 | 0.87 | GAA (0.40) | GPR142MMERAB9A | |
| SCHEMBL466340 | 0.87 | GAA (0.40) | GPR142MMERAB9A | |
| SCHEMBL1643961 | 0.87 | GAA (0.40) | GPR142MMERAB9A | |
| SCHEMBL9238392 | 0.86 | GGT1 (0.47) | GGT1GPR142MMEACE | |
| SCHEMBL2980934 | 0.85 | CPB2 (0.38) | GGT1CPB2KMT2ACPB1MEN1 | |
| SCHEMBL2974157 | 0.84 | CPB2 (0.38) | GGT1GPR142CPB2KMT2ACPB1 | |
| SCHEMBL5870219 | 0.84 | MME (0.59) | MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2490709-B1 | PEPTIDIC GLP-2 AGONISTS | FERRING BV (NL) | 2014-11-26 | — | — | EP | disclosed |
| US-8580918-B2 | Peptidic GLP-2 agonists | FERRING B.V. (NL) | 2013-11-12 | — | — | US | disclosed |
| US-20120231999-A1 | PEPTIDIC GLP-2 AGONISTS | FERRING B.V. (NL) | 2012-09-13 | — | — | US | disclosed |
| EP-2314616-A1 | Peptidic GLP-2 agonists | Ferring B.V. (NL) | 2011-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120231999-A1 | PEPTIDIC GLP-2 AGONISTS | GLP1R, GIPR, IAPP | GGT1 1812/4885GPR142 90/4885SIGMAR1 2487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.